AK 10

Drug Profile

AK 10

Alternative Names: AK10

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aetas Pharma
  • Class Heart failure therapies
  • Mechanism of Action Troponin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Acute heart failure; Chronic heart failure

Most Recent Events

  • 03 Aug 2017 Early research in Acute heart failure in Japan before August 2017 (Aetas Pharma pipeline, August 2017)
  • 03 Aug 2017 Early research in Chronic heart failure in Japan before August 2017 (Aetas Pharma pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top